Dissemin is shutting down on January 1st, 2025

Published in

Wiley Open Access, Journal of Cellular and Molecular Medicine, 5b(12), p. 2015-2026, 2008

DOI: 10.1111/j.1582-4934.2008.00200.x

Wiley Open Access, Journal of Cellular and Molecular Medicine, 6b(12), p. 2586-2597, 2008

DOI: 10.1111/j.1582-4934.2008.00195.x

Links

Tools

Export citation

Search in Google Scholar

Effect of homocysteine on calcium mobilization and platelet function in type 2 diabetes mellitus

Journal article published in 2008 by N. Alexandru, I. Jardin, D. Popov, M. Simionescu, J. García-Estañ ORCID, G. M. Salido, J. A. Rosado
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Type 2 diabetes mellitus induces a characteristic platelet hyperactivity that might be due to several factors including oxidative stress and abnormal intracellular Ca(2+) homeostasis. Hyperhomocysteinaemia is considered a risk factor in the development of thrombosis although its effect on platelet function and the mechanisms involved are still poorly understood. Here we show that homocysteine induce a concentration-dependent increase in endogenous production of reactive oxygen species (ROS), which was significantly greater in platelets from diabetic patients than in controls. Platelet treatment with homocysteine resulted in Ca2+ release from the dense tubular system and the acidic stores. Ca2+ mobilization-induced by homocysteine consisted in two components, an initial slow increase in intracellular free Ca (+) concentration ([Ca2+]i) and a rapid and marked increase in [Ca2+]i, th second leading to the activation of platelet aggregation. As well as ROS generation, Ca2+ mobilization and platelet aggregation were significantly greater in platelets from diabetic donors than in controls, which indicate that platelets from diabetic donors are more sensitive to homocysteine. These findings, together with the hyperhomocysteinaemia reported in diabetic patients, strongly suggest that homocysteine might be considered a risk factor in the development of cardiovascular complications associated to type 2 diabetes mellitus.